Orchestra BioMed announces continued expansion of global property estate

Orchestra BioMed (OBIO) announced continued expansion of its global intellectual property estate supporting its proprietary AVIM therapy pipeline. Over the past 12 months, the Company has secured 10 new patents related to treatment of hypertension. The Company has also secured a total of 17 patents covering application of the technology for treatment of heart failure, significantly expanding the reach of its IP platform. “We are very proud of the continued expansion of our intellectual property portfolio supporting AVIM therapy, which we are actively evaluating for the treatment of hypertension in the BACKBEAT global pivotal study in collaboration with Medtronic,” commented David Hochman, Chairman and Chief Executive Officer of Orchestra BioMed. “Over the past year, we have strengthened our patent estate with ten newly issued patents covering the treatment of hypertension. Our issued hypertension-specific patent portfolio is now 120 patents strong and we expect it to continue to grow in the future. Equally exciting is our growing heart failure treatment patent estate which is now comprised of seventeen issued patents. This extraordinary array of intellectual property reflects our strategic commitment to protect our proprietary, high-impact device-based therapy which we believe can help physicians better address the needs of patients with hypertension, the leading global risk factor for death, as well as heart failure, which affects more than 64 million people worldwide.”